Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 8/20 | 0.74 |
| ▸ | PTGS2 | P35354 | 14/20 | 0.70 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9088240 | 0.89 | PTGS2 (0.64) | PTGS1PTGS2PDPK1CYP2C9CYP1A2 | |
| SCHEMBL25150243 | 0.88 | PTGS2 (0.72) | PTGS1PTGS2PDPK1CYP2C9CYP3A4 | |
| SCHEMBL9273738 | 0.88 | PTGS2 (0.72) | PTGS1PTGS2CYP2C9CYP1A2CYP3A4 | |
| SCHEMBL9208582 | 0.87 | PTGS2 (0.74) | PTGS1PTGS2PDPK1CYP2C9CYP3A4 | |
| SCHEMBL5147701 | 0.87 | PTGS2 (0.71) | PTGS1PTGS2PDPK1CYP2C9CYP1A2 | |
| SCHEMBL6451398 | 0.85 | PTGS1 (1.00) | PTGS1PTGS2PDPK1MAPT | |
| SCHEMBL8641532 | 0.85 | PTGS2 (0.69) | PTGS1PTGS2MAPTCYP2C9 | |
| SCHEMBL9201352 | 0.85 | PTGS2 (0.68) | PTGS1PTGS2CYP2C9 | |
| SCHEMBL5344449 | 0.85 | PTGS1 (0.80) | PTGS1PTGS2PDPK1MAPTCYP2C9 | |
| SCHEMBL7461307 | 0.84 | PTGS2 (0.67) | PTGS1PTGS2PDPK1CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492773-B1 | 4-(HETEROCYCLYL)-BENZENESULFOXIMINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | CADILA HEALTHCARE LTD (IN) | 2009-02-04 | — | — | EP | disclosed |
| US-7348342-B2 | Heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2008-03-25 | — | — | US | disclosed |
| US-20050277678-A1 | Heterocyclic compounds process for their preparation and pharmceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2005-12-15 | — | — | US | disclosed |
| EP-1492773-A2 | 4-(HETEROCYCLYL)-BENZENESULFOXIMINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | CADILA HEALTHCARE LTD. (IN) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003087062-A2 | 4-(HETEROCYCLYL)-BENZENESULFOXIMINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | CADILA HEALTHCARE LIMITED (IN) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277678-A1 | Heterocyclic compounds process for their preparation and pharmceutical compositions containing them and their use in medicine | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HPGDS, LTC4S | PTGS1 22/4885PTGS2 27/4885PDPK1 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.